VectorXcellerator Programme: Fully funded feasibility studies to support early-stage cell and gene therapy programmes

Webinar: Optimising viral vector manufacturing with CDMO expertise and innovation

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Risks of replication-competent retro/lentivirus from associated vector systems: Is it time for a roadmap toward reduced testing?

April 21, 2026